Insider Selling: Medpace (NASDAQ:MEDP) Director Sells 6,472 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Robert Kraft sold 6,472 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the sale, the director directly owned 833 shares in the company, valued at $493,011.05. The trade was a 88.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Stock Performance

Shares of MEDP traded up $4.42 during trading hours on Tuesday, hitting $590.18. The stock had a trading volume of 219,107 shares, compared to its average volume of 415,017. The firm has a 50-day moving average price of $541.26 and a 200 day moving average price of $426.46. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $625.00. The firm has a market capitalization of $16.62 billion, a price-to-earnings ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same quarter in the prior year, the firm posted $3.01 earnings per share. The company’s revenue was up 23.7% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Medpace

A number of institutional investors and hedge funds have recently bought and sold shares of MEDP. Nordea Investment Management AB raised its holdings in shares of Medpace by 4.8% during the 2nd quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock worth $19,067,000 after acquiring an additional 2,792 shares during the period. Arkadios Wealth Advisors purchased a new stake in shares of Medpace in the 2nd quarter valued at approximately $327,000. Inspire Investing LLC acquired a new stake in shares of Medpace during the 1st quarter worth approximately $2,059,000. Truist Financial Corp raised its position in shares of Medpace by 10.2% during the 2nd quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock valued at $4,048,000 after buying an additional 1,197 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Medpace by 10.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company’s stock valued at $371,000 after buying an additional 111 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent analyst reports. TD Cowen increased their price target on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 27th. Mizuho lifted their price target on shares of Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Robert W. Baird set a $613.00 target price on shares of Medpace in a research report on Friday, October 24th. Finally, Barclays upped their price target on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a research report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.